149 related articles for article (PubMed ID: 34153224)
1. Functional assessment of the effects of CYP3A4 variants on acalabrutinib metabolism in vitro.
Han M; Qian J; Ye Z; Xu R; Chen D; Xie S; Cai J; Hu G
Chem Biol Interact; 2021 Aug; 345():109559. PubMed ID: 34153224
[TBL] [Abstract][Full Text] [Related]
2. Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro.
Han M; Zhang X; Ye Z; Wang J; Qian J; Hu G; Cai J
Chem Biol Interact; 2021 Dec; 350():109700. PubMed ID: 34648813
[TBL] [Abstract][Full Text] [Related]
3. Genetic variations of CYP3A4 on the metabolism of itraconazole in vitro.
Xie SL; Zhu X; Gao N; Lin Q; Chen C; Yang YJ; Cai JP; Hu GX; Xu RA
Food Chem Toxicol; 2023 Nov; 181():114101. PubMed ID: 37863381
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro.
Cai Y; Lin Q; Jin Z; Xia F; Ye Y; Xia Y; Papadimos TJ; Wang Q; Hu G; Cai J; Chen L
Chem Res Toxicol; 2021 Jan; 34(1):103-109. PubMed ID: 33393779
[TBL] [Abstract][Full Text] [Related]
5. Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.
Xu RA; Wen J; Tang P; Wang C; Xie S; Zhang BW; Zhou Q; Cai JP; Hu GX
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):383-387. PubMed ID: 29117640
[TBL] [Abstract][Full Text] [Related]
6. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants.
Akiyoshi T; Saito T; Murase S; Miyazaki M; Murayama N; Yamazaki H; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Dispos; 2011 Apr; 39(4):724-8. PubMed ID: 21212239
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro.
Lin QM; Li YH; Lu XR; Wang R; Pang NH; Xu RA; Cai JP; Hu GX
Chem Res Toxicol; 2019 Aug; 32(8):1583-1590. PubMed ID: 31293154
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.
Xu L; Yu S; Liu H; Yi B; Wang G; Liu Y
Eur J Clin Pharmacol; 2022 Sep; 78(9):1435-1446. PubMed ID: 35680661
[TBL] [Abstract][Full Text] [Related]
10. Comparison of catalytic properties of cytochromes P450 3A4 and 3A5 by molecular docking simulation.
Niwa T; Yasumura M; Murayama N; Yamazaki H
Drug Metab Lett; 2014; 8(1):43-50. PubMed ID: 24484539
[TBL] [Abstract][Full Text] [Related]
11. Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro.
Li YH; Lu XR; Lin QM; Huang HL; Liang XL; Cai JP; Cui J; Hu GX
J Pharm Pharmacol; 2019 Nov; 71(11):1677-1683. PubMed ID: 31441067
[TBL] [Abstract][Full Text] [Related]
12. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.
Chen X; Pan LQ; Naranmandura H; Zeng S; Chen SQ
PLoS One; 2012; 7(6):e38495. PubMed ID: 22719896
[TBL] [Abstract][Full Text] [Related]
13. Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism.
Yuan LJ; Li XY; Ni JH; Wang J; Xu XY; Luo JC; Zhou Q; Hu GX; Cai JP; Qian JC
Toxicol Appl Pharmacol; 2023 Sep; 475():116653. PubMed ID: 37574146
[TBL] [Abstract][Full Text] [Related]
14. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5.
Niwa T; Murayama N; Emoto C; Yamazaki H
Curr Drug Metab; 2008 Jan; 9(1):20-33. PubMed ID: 18220568
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants.
Yamaguchi Y; Akiyoshi T; Kawamura G; Imaoka A; Miyazaki M; Guengerich FP; Nakamura K; Yamamoto K; Ohtani H
Drug Metab Pharmacokinet; 2021 Jun; 38():100384. PubMed ID: 33826998
[TBL] [Abstract][Full Text] [Related]
16. Functional assessment of
Fang P; Tang PF; Xu RA; Zheng X; Wen J; Bao SS; Cai JP; Hu GX
Drug Des Devel Ther; 2017; 11():3503-3510. PubMed ID: 29263648
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Steroid Hormone Hydroxylations by and Docking to Human Cytochromes P450 3A4 and 3A5.
Niwa T; Narita K; Okamoto A; Murayama N; Yamazaki H
J Pharm Pharm Sci; 2019; 22(1):332-339. PubMed ID: 31339834
[TBL] [Abstract][Full Text] [Related]
18. Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6
Kumondai M; Gutiérrez Rico EM; Hishinuma E; Ueda A; Saito S; Saigusa D; Tadaka S; Kinoshita K; Nakayoshi T; Oda A; Abe A; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2021 Mar; 49(3):212-220. PubMed ID: 33384383
[TBL] [Abstract][Full Text] [Related]
19. Identification and Characterization of ACP-5862, the Major Circulating Active Metabolite of Acalabrutinib: Both Are Potent and Selective Covalent Bruton Tyrosine Kinase Inhibitors .
Podoll T; Pearson PG; Kaptein A; Evarts J; de Bruin G; Emmelot-van Hoek M; de Jong A; van Lith B; Sun H; Byard S; Fretland A; Hoogenboom N; Barf T; Slatter JG
J Pharmacol Exp Ther; 2023 Jan; 384(1):173-186. PubMed ID: 36310034
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
